Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07229027

Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.

Status
Recruiting
Phase
Study type
Observational
Enrollment
500 (estimated)
Sponsor
Medialis Ltd. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity.

Detailed description

Despite evidence on the burden of BMI \>25, few disease-specific instruments comprehensively capture its multidimensional impact. Existing frameworks often target obesity (BMI ≥30) or patients on pharmacological or surgical therapy. Overweight and extremely obese populations are underrepresented, and economic and psychosocial dimensions are rarely integrated into severity staging. This study, therefore, aims to systematically evaluate symptoms, comorbidities, HRQoL, and costs across the full spectrum of individuals with BMI \>25, excluding those on GLP-1 therapy. Integrating clinician and patient perspectives will support the development of more inclusive severity measures and inform early intervention strategies.

Conditions

Timeline

Start date
2025-11-01
Primary completion
2026-07-01
Completion
2026-08-01
First posted
2025-11-14
Last updated
2025-11-14

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT07229027. Inclusion in this directory is not an endorsement.